Identifying surrogate endpoints for use in clinical trials that strongly predict clinical outcomes such as improved survival and quality of life is challenging.
Identifying surrogate endpoints for use in clinical trials that strongly predict clinical outcomes such as improved survival and quality of life is challenging.
Last year, the FDA approved almost a dozen novel cancer drugs and expanded indications for many more, while growing agency scrutiny led to numerous withdrawals.
Immunotherapy with checkpoint inhibitors has been a game changer for some cancer types, but development of this drug class has been uncoordinated and problematic, say FDA officials.
To Stay: Two More Cancer Indications With Dangling Approvals medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.